Literature DB >> 23883707

Use of GenoType® MTBDRplus assay to assess drug resistance and mutation patterns of multidrug-resistant tuberculosis isolates in northern India.

A K Maurya1, A K Singh, S Kant, J Umrao, M Kumar, R A S Kushwaha, V L Nag, T N Dhole.   

Abstract

PURPOSE: The emergence and spread of multidrug-resistant tuberculosis (MDR-TB) is a major public health problem. The diagnosis of MDR-TB is of paramount importance in establishing appropriate clinical management and infection control measures. The aim of this study was to evaluate drug resistance and mutational patterns in clinical isolates MDR-TB by GenoType® MTBDRplus assay.
MATERIAL AND METHODS: A total of 350 non-repeated sputum specimens were collected from highly suspected drug-resistant pulmonary tuberculosis (PTB) cases; which were processed by microscopy, culture, differentiation and first line drug susceptibility testing (DST) using BacT/ALERT 3D system.
RESULTS: Among a total of 125 mycobacterium tuberculosis complex (MTBC) strains, readable results were obtained from 120 (96%) strains by GenoType® MTBDRplus assay. Only 45 MDR-TB isolates were analysed for the performance, frequency and mutational patterns by GenoType® MTBDRplus assay. The sensitivity of the GenoType® MDRTBplus assay for detecting individual resistance to rifampicin (RIF), isoniazid (INH) and multidrug resistance was found to be 95.8%, 96.3% and 97.7%, respectively. Mutation in codon S531L of the rpoB gene and codon S315T1 of katG genes were dominated in MDR-TB strains, respectively (P < 0.05).
CONCLUSIONS: The GenoType® MTBDRplus assay is highly sensitive with short turnaround times and a rapid test for the detection of the most common mutations conferring resistance in MDR-TB strains that can readily be included in a routine laboratory workflow.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23883707     DOI: 10.4103/0255-0857.115625

Source DB:  PubMed          Journal:  Indian J Med Microbiol        ISSN: 0255-0857            Impact factor:   0.985


  7 in total

1.  Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis.

Authors:  V R Bollela; E I Namburete; C S Feliciano; D Macheque; L H Harrison; J A Caminero
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

2.  Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.

Authors:  S B Georghiou; M Seifert; D Catanzaro; R S Garfein; F Valafar; V Crudu; C Rodrigues; T C Victor; A Catanzaro; T C Rodwell
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

3.  Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa.

Authors:  Nontuthuko E Maningi; Lesibana A Malinga; John F Antiabong; Ruth M Lekalakala; Nontombi M Mbelle
Journal:  BMC Infect Dis       Date:  2017-12-28       Impact factor: 3.090

4.  Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda.

Authors:  Edgar Kigozi; George W Kasule; Kenneth Musisi; Deus Lukoye; Samuel Kyobe; Fred Ashaba Katabazi; Eddie M Wampande; Moses L Joloba; David Patrick Kateete
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

5.  Mutations in Mycobacterium tuberculosis Isolates with Discordant Results for Drug-Susceptibility Testing in Peru.

Authors:  L Solari; D Santos-Lazaro; Z M Puyen
Journal:  Int J Microbiol       Date:  2020-04-06

6.  Rapid detection of multidrug resistant tuberculosis in respiratory specimens at a tertiary care centre in south coastal Karnataka using Genotype MTBDR plus assay.

Authors:  Vishnu Prasad Shenoy; Ajay Kumar; Kiran Chawla
Journal:  Iran J Microbiol       Date:  2018-10

7.  Analysis of drug resistance mutations in pulmonary Mycobacterium tuberculosis isolates in the Southern coastal region of Andhra Pradesh, India.

Authors:  Giri Prasad Polu; Jasmine Mohammad Shaik; Neela Mani Kanta Kota; Deepthi Karumanchi; Uday Sankar Allam
Journal:  Braz J Infect Dis       Date:  2019-08-14       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.